Special Edition — Key Presentations from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Ovarian Cancer Issue
Oncology Today with Dr Neil Love
00:00
The Role of PARP in Ovarian Cancer
The best data is the RAT51CRD. Similar, Braca, it a little bit more higher incidence than PALB2, Brip and BARD. Those patients should already be HRD test positive. But if you had any doubt about utilizing a PARP inhibitor in my mind, that should eliminate it in making sure.
Transcript
Play full episode
